Patent: 10,188,692
✉ Email this page to a colleague
Summary for Patent: 10,188,692
Title: | Methods and compositions for preventing or treating ophthalmic conditions |
Abstract: | The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. |
Inventor(s): | Liu; Liping (Manassas, VA), Tang; Shibo (Guangzhou, CN), Liang; Xiaoling (Guangzhou, CN) |
Assignee: | Stealth Biotherapeutics Corp (Monaco, MC) |
Application Number: | 15/401,527 |
Patent Claims: | see list of patent claims |
Details for Patent 10,188,692
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2029-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2029-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2029-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2029-08-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |